Nexien BioPharma, Inc.

NXEN

US65343D1000

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 15:25:09 14/05/2024 BST			5-day change	1st Jan Change
0.0163 ^USD	0.00%		0.00%	-37.07%

02-20	Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021

October 12, 2021 at 11:16 am

Nexien BioPharma, Inc. announced earnings results for the full year ended June 30, 2021. For the full year, the company announced net loss was USD 1.859 million compared to USD 2.671 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.05 a year ago.

Latest news about Nexien BioPharma, Inc.

Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-20	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/09/23	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	17/05/23	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	08/02/23	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	09/11/22	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	28/09/22	CI
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	27/09/22	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	12/05/22	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	08/02/22	CI
Nexien BioPharma, Inc. announced that it has received $0.15 million in funding from Quick Capital, LLC	17/01/22	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	22/11/21	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	12/10/21	CI
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	11/10/21	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	05/05/21	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020	11/02/21	CI
Nexien Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2020	10/11/20	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020	28/09/20	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020	14/05/20	CI
Nexien BioPharma, Inc. Announces Management Changes	06/04/20	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019	12/02/20	CI
Nexien Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	12/11/19	CI
Nexien BioPharma, Inc. Announces Resignation of Courtney Clark from Director	22/10/19	CI
Intiva Biopharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	30/09/19	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2019	14/05/19	CI

Chart Nexien BioPharma, Inc.

Duration

Period

More charts

Company Profile

Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEXIEN BIOPHARMA, INC.	-37.07%	1.1M
ELI LILLY AND COMPANY	+31.06%	688B
NOVO NORDISK A/S	+30.35%	588B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	326B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	239B
NOVARTIS AG	+10.16%	210B
ROCHE HOLDING AG	-8.14%	200B
AMGEN INC.	+8.12%	167B